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Abstract: 
The purpose of this study was to assess the effect of interferential current (IFC) on perceived 
pain and serum cortisol levels in subjects with delayed onset muscle soreness (DOMS). DOMS 
was induced in 10 subjects through repeated eccentric contractions of the elbow flexors. Forty-
eight hours later subjects were evaluated. Starting at t = 0:00, blood samples were withdrawn 
from a superficial vein every 5 mitt for 65 min. At t = 0:05, subjects received IFC of 10 bps or 
IFC of 100 bps. Perceived pain levels were evaluated prior to catheter insertion and at t = 0:35, 
0:50, and 0:65. Two mixed-model analyses of variance revealed a significant decrease in 
perceived pain scores across time for both treatment groups but no significant difference in 
serum cortisol for the two groups. It was concluded that IFC of high and low beat frequency is 
effective in controlling the pain of DOMS but does not elicit a generalized stress response as 
indexed by increasing serum cortisol levels. 
 
Article: 
Little information is available on the ability of interferential current (IFC) to relieve pain from 
musculoskeletal injuries (27). The mechanism of how IFC devices control pain is not truly 
understood. 
 
IFC has an advantage over traditional transcutaneous electrical nerve stimulation (TENS) 
because the medium frequencies used in IFC encounter less resistance at the skin and have better 
current conductance through the skin than the low frequencies used in TENS (15, 16). Therefore, 
the cutaneous nerves are apparently less irritated (9, 19). 
 
Much of the clinical work done with IFC involves pain control (4, 27). Due to the physical 
properties of IFC in body tissues, it may be able to produce analgesia via activation of the 
hypothalamic—pituitary—adrenal (HPA) axis. Pain arises as A-delta and unmyelinated C fibers 
send afferent signals primarily to laminae I and V in the spinal cord. The contralateral 
spinothalamic tract is the major nociceptive pathway to the thalamus with the cells of origin 
concentrated in laminae I and V (16). Under certain pathological conditions, the sensitivity of 
sensory nerve endings or receptors increases dramatically and is attributed to the release of pain- 
inducing substances, including bradykinin, serotonin, and prostaglandins (21). 
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Delayed onset muscle soreness (DOMS) is the sensation of discomfort or pain in the skeletal 
muscles that occurs following unaccustomed muscular exertion (1). Most soreness increases in 
intensity in the first 24 hr postexercise, peaks in intensity from 24 to 72 hr, and subsides in 5 to 7 
days postexercise (1). DOMS has been attributed to increased tension in contractile elements that 
physically damages the structural components of the muscle (1). Using a series of eccentric 
muscular contractions, researchers have shown that DOMS is easily induced in the elbow flexors 
in subjects (5, 6, 7, 13). 
 
With the identification of the endogenous opioid beta-endorphin, a new theory was proposed that 
electrical currents of low frequency and high intensity would elicit the release of beta-endorphin 
from the anterior pituitary and produce an analgesic response (3). Castel (3) proposed that an 
endogenous opioid, such as beta- endorphin, is released by a variety of factors from the anterior 
pituitary gland. Many authors have suggested that a current of high intensity and low frequency 
is ideal for eliciting analgesia via systemically released endogenous opioid peptide (3, 16, 21, 
23). 
 
Beta-endorphin is released from the anterior pituitary gland. It shares the precursor hormone 
proopiomelanocortin (POMC) with adrenocorticotropin (ACTH). ACTH results in the synthesis 
and release of cortisol from the adrenal cortex (2). Because of the difficulty of conducting and 
interpreting the beta-endorphin assay, ACTH and cortisol have been used as markers of beta-
endorphin release (7, 16). 
 
The purpose of this study was to compare the ability of IFC of high and low beat frequency to 
control mu sculoskeletal pain as measured by perceived pain scales and serum cortisol levels as 
an approximation of generalized stress; we used delayed onset muscle soreness as a model of 
injury. 
 
METHODS 
Subjects 
Ten healthy subjects (5 male and 5 female) (height 170.9 ± 7.5 cm, weight 64.8 ± 10.4 kg, age 
22.8 ± 2.5 years) with no recent history of upper extremity injury, disability, or pain were 
recruited from the student population at the University of Virginia. Each subject read and signed 
an informed consent form in compliance with the University of Virginia Human Investigation 
Committee. All were informed of the purpose of the study, and each was assigned a code 
number. In no instance was the name of the subject associated with the results. 
 
Procedures 
All subjects reported to the athletic training laboratory for the exercise portion of the study 
between 15:00 and 16:00 hr. To induce DOMS, subjects repeatedly lowered 11.4-kg weights 
through eccentric contraction from full flexion to complete extension in 3 s with their 
nondominant limb. This continued until subjects could not maintain the 3-s interval, at which 
time the weight was decreased 2.3 kg. This continued until subjects reached 2.3 kg, at which 
time the subjects continued until exhaustion or until 20 repetitions were completed. A technician 
performed all concentric lifting of the weight to avoid premature fatigue. Subjects were 
instructed to refrain from the use of any anti-inflammatory and analgesic agents or modalities for 
the duration of the study. 
 
Forty-eight hours following the exercise session, subjects returned to the Clinical Research 
Center laboratory at 14:00 hr. Time of treatment was standardized to control for diurnal 
variations in cortisol. Subjects were then randomly placed into one of two groups. One group (n 
= 5) received low beat frequency current of 10 bps for 30 min. A second group (n = 5) received 
high beat frequency current of 100 bps for 30 min. 
 
At the beginning of the evaluation, subjects were assessed for levels of perceived pain using the 
scale described by Talag (26). Perceived pain levels were also obtained immediately and 15 and 
30 min following treatment. 
 
Following skin preparation, a venous catheter was inserted into the unexercised arm in a 
superficial vein. Four electrodes (carbon rubber, 3 in. round) were placed about the biceps in 
quadripolar fashion on the exercised arm. Two were placed at the proximal musculotendinous 
junction (one medial and one lateral) and two were placed at the distal musculotendinous 
junction (one medial and one lateral). The subjects then sat quietly for 60 min. One 2-m1 blood 
sample was taken at the end of the 60 min, This first sample served as the zero time indicator for 
the treatment session (t = 0:00). At t = 0:05, another 2-ml sample was obtained, and the IFC 
treatment with an Intellect Model 775 MP IFC Unit (Chattanooga Corp., Hixson, TN) 
commenced. The intensity of current in the low-frequency group was set to maximal subject 
tolerance. Subject tolerance was defined as the point at which the level of current in the tissue 
became uncomfortable. This level of current resulted in motor recruitment in all subjects. 
Intensity of the high-frequency group was set just below motor recruitment (15, 20). We 
explained this to the subject by stating that if he or she experienced a muscle contraction, the 
intensity was too high and must be lowered. Two-milliliter blood samples were taken every 5 
min throughout the 30-min treatment span. Following the IFC treatment, subjects were 
monitored for an additional 30 min during which time blood sampling was continued. Following 
the final sample (t = 0:65), the catheter was removed and direct pressure was administered until 
bleeding ceased. 
 
Blood samples were centrifuged at 2,500 rpm for 15 min, and the resultant serum was pipetted 
and stored at —15 °C for analysis. All analyses for cortisol were performed using a standard 
radioimmunoassay technique (DPC Products, Los Angeles). The minimal detectable amount of 
serum cortisol is 0.8 jig/d1 for the assay used. The coefficient of variation varied between 6.2 
and 10.2% throughout the working range of the assay. 
 
STATISTICAL ANALYSIS 
A mixed-model ANOVA (one between, one within) was computed for the perceived pain data. 
Serum cortisol levels were plotted over time, and the area under the curve for treatment (Samples 
1-7, t = 0:00 to t = 0:30) and posttreatment (Samples 8-14, t = 0:35 to t = 0:65) was calculated 
using the procedure described by Veldhuis and Johnson (29). A mixed-model ANOVA (one 
between, one within) was also computed for the cortisol values obtained by subtracting treatment 
from posttreatment. A Pearson Product Moment correlation value was computed for perceived 
pain and 48-hr cortisol levels. 
 
RESULTS 
The ANOVA revealed a significant decrease of perceived pain levels across time (Figure 1) in 
both treatment protocols, F(3, 24) = 25.561, p = .0001, but perceived pain levels did not differ 
significantly between treatment groups, F(1, 8) = 4.556, p = .0651. 
 
Figure 1— A comparison of the effect of WC of high and low beat frequency on perceived pain levels. 
 
Figure 2 —A comparison of the effect of IFC of high and low beat frequency on serum cortisol levels. 
 
There was no difference in cortisol levels between treatment groups, F(1, 8) = 0.250, p = .631, 
and no mean effect of pre- to posttreatment was observed, F(1, 8) = 0.031, p = .864. Figure 2 
presents the cortisol data. The Pearson Product Moment correlation revealed no significant 
correlation between perceived pain and 48-hr cortisol levels (r = .257, R2 = .066, p > .05). 
 
DISCUSSION 
We found that IFC of high and low beat frequency significantly decreased perceived pain levels 
across time in both treatment groups. However, neither high or low beat frequency treatment 
protocols had a significant acute effect to raise serum cortisol levels. 
 
Cortisol values ranged from 4.2 to 19.5 µg/dl (normal clinical range = 2-10 μg/d1). These data 
resulted in very large standard deviations, as demonstrated by Figure 2. The pretreatment levels 
were within normal range for the time of day. This demonstrated that the stress of DOMS at the 
48-hr mark is much different than the stress brought about by an acute injury that would acutely 
raise cortisol levels (11). 
 
A reason for failure of cortisol level elevation may be the intrinsic factors of the IFC used in this 
study. The unit that was used to deliver IFC in this study operated with a carrier frequency of 
5000 Hz. The resulting phase duration of the current study was 100 μs. A current with this phase 
duration may not be able stimu-current study was 100 μs. A current with this phase duration may 
not be able stimulate the A-delta and C fibers that travel to the HPA axis. This value is at or 
below suggested parameters (21). 
 
The reduction in pain levels for both groups suggests that pain control was achieved regardless 
of the IFC treatment protocol. One explanation may be the gate control theory of pain suggested 
by Melzack and Wall (18). According to this theory, activity in afferent large diameter fibers (A-
beta and A-alpha) projects to the substantia gelatinosa (SG) of the dorsal horn of the spinal cord. 
The large diameter fibers then inhibit the input of nociception fibers (A-delta and C) to the first 
transmission cell. Kloth (16) suggested that if a beat frequency of 2 bps is selected and adjusted 
to produce a comfortable tingling paresthesia without muscle contraction, then A-beta and A-
alpha fibers would be recruited. 
 
Another limitation of this study was that no placebo group was used. Therefore, the reduction of 
pain in both treatment groups may be due to a placebo effect. Another possible explanation for 
the reduction of pain may be peripheral mechanisms acting upon primary afferent nerves that 
may be potential targets for circulating beta-endorphin produced by the anterior pituitary (14, 22, 
24). 
 
That there was no significant correlation between perceived pain and cortisol levels at 48 hr 
postexercise suggests that our method of DOMS induction has no effect over cortisol release 
after the acute stage. 
 
The failure to elevate cortisol levels acutely via IFC treatment in our subjects suggests that 
POMC was not released from the anterior pituitary gland, although present data do not rule out 
such a mechanism. This is in agreement with others who have reported that TENS-induced pain 
control was not reversed by the opiate antagonist naloxone hydrochloride (8, 20), although 
neither of these studies used IFC as the stimulating current. 
 
Within the central nervous system, the major physiological role of the endogenous opioid 
peptides, including beta-endorphin, is thought to be pain modulation by binding to specific 
opiate receptors and blocking pain transmission in afferent neurons at the spine and supraspinal 
levels (2). However, the role of opioid peptide synthesized in the anterior pituitary gland and 
released into the systemic circulation is much less clear (2, 12, 25, 28). It has been suggested that 
ACTH and beta-endorphins are released concomitantly into the peripheral circulation (2, 17). 
Malizia et al. (17) studied the effect of electroacupuncture on peripheral ACTH and beta-
endorphin levels and found that both rose in response to electroacupuncture. Guillemin et al, (10) 
studied the effect of peripheral ACTH and beta-endorphin levels in the responses of male rats to 
acute stress and found that ACTH and beta-endorphin levels did rise concomitantly. 
 
CONCLUSION 
Both high and low beat frequency IFC reduced perceived pain levels across time. Once again, 
this may be due to a placebo effect; no placebo treatment was used in the investigation. No 
significant effect existed with low beat frequency or high beat frequency IFC with respect to 
eliciting the central release of cortisol into the circulation. These data are not consistent with (but 
do not rule out) the theory that TENS of a low frequency and high intensity will elicit the release 
of POMC. Continued use of this therapeutic modality for pain modulation necessitates a more 
complete understanding of how this modality modulates pain, which requires properly controlled 
studies in the future. 
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